Waters Corporation
General ticker "WAT" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $20.7B (TTM average)
Waters Corporation follows the US Stock Market performance with the rate: 31.4%.
Estimated limits based on current volatility of 1.5%: low 305.70$, high 316.58$
Factors to consider:
- Company included in S&P500 list
- Total employees count: 8200 (+3.8%) as of 2024
- China accounted for 13.5% of revenue in the fiscal year ended 2024-12-31
- US accounted for 31.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Currency fluctuations, Geopolitical risks, Public health crises, Supply chain disruptions, Economic downturns and volatility
- Current price 13.0% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [347.72$, 470.66$]
- 2026-12-31 to 2027-12-31 estimated range: [377.55$, 507.18$]
Financial Metrics affecting the WAT estimates:
- Negative: with PPE of 29.1 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 28.22 > 18.38
- Positive: Return on assets ratio (scaled to [-100,100]) of 11.22 > 6.11
- Positive: Interest expense per share per price, % of 0.22 <= 0.73
- Positive: 0.01 < Operating cash flow per share per price, % of 2.87
- Positive: 42.68 < Shareholder equity ratio, % of 50.38 <= 64.29
- Negative: Industry inventory ratio change (median), % of 0.45 > 0.31
Short-term WAT quotes
Relationship graph
Long-term WAT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $2,956.42MM | $2,946.82MM | $3,165.29MM |
| Operating Expenses | $2,138.74MM | $2,120.47MM | $2,272.06MM |
| Operating Income | $817.68MM | $826.35MM | $893.22MM |
| Non-Operating Income | $-81.43MM | $-71.48MM | $-138.34MM |
| Interest Expense | $98.86MM | $89.68MM | $50.77MM |
| R&D Expense | $174.94MM | $183.03MM | $195.18MM |
| Income(Loss) | $736.24MM | $754.87MM | $754.88MM |
| Taxes | $94.01MM | $117.03MM | $112.25MM |
| Profit(Loss)* | $642.23MM | $637.83MM | $642.63MM |
| Stockholders Equity | $1,150.34MM | $1,828.51MM | $2,561.24MM |
| Inventory | $516.24MM | $477.26MM | $572.37MM |
| Assets | $4,626.85MM | $4,553.80MM | $5,083.98MM |
| Operating Cash Flow | $602.81MM | $762.12MM | $652.55MM |
| Capital expenditure | $160.63MM | $142.48MM | $112.75MM |
| Investing Cash Flow | $-1,442.27MM | $-144.02MM | $-152.25MM |
| Financing Cash Flow | $754.95MM | $-696.67MM | $-237.21MM |
| Earnings Per Share** | $10.87 | $10.75 | $10.80 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.